학술논문
Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
Document Type
article
Author
Source
OncoTargets and Therapy, Vol Volume 16, Pp 133-139 (2023)
Subject
Language
English
ISSN
1178-6930
Abstract
Meshaal Alanzi,1 Mohammad Abu-Tineh,2 Lajos Szabados,3 MZ Sharaf Eldean,4 Sali Alatasi,4 Ruba Y Taha,2 Sarah A Elkourashy2,5 1Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar; 2Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar; 3Department of Nuclear Medicine, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar; 4Department of Pathology, Hamad Medical Corporation, Doha, Qatar; 5Weill Cornell Medicine University, Doha, QatarCorrespondence: Meshaal Alanzi, Internal Medicine Resident, Hamad Medical Corporation, Al Rayan Road, Doha, Qatar, Tel +97455159061, Email m.alanzi93@gmail.comAbstract: Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.Keywords: Burkitt’s lymphoma, polatuzumab, Lymphoma, anti CD79b, resistant lymphoma